# A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

> **NCT00434642** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 484 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Bevacizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00434642
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-09
- **Final completion:** 2013-07
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434642, "A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00434642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*